Clinical relevance of tumor markers for the control of chemotherapy

Anticancer Research

Volumn 25, Issue 3 A, 2005, Pages 1655-1658

  Finek, Jindrich ^a,c   Holubec Jr , L ^a   Topolcan, O ^a   Salvet, J ^a   Pikner, R ^a   Holdenrieder, S ^b   Stieber, P ^b   Lamerz, R ^b   Holubec Sen, L ^a   Svobodova, S ^a   Visokai, V ^a   Helmichova, E ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c University of Munich ^*  (Czech Republic)

Author keywords

Biological markers; Breast cancer; Chemotherapy control; Colorectal cancer; Ovarian cancer

Indexed keywords

ANTIGEN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MESSENGER RNA; TISSUE POLYPEPTIDE ANTIGEN; TISSUE POLYPEPTIDE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; BIOLOGICAL ACTIVITY; BLOOD LEVEL; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CELL PROLIFERATION; CONFERENCE PAPER; HUMAN; MAJOR CLINICAL STUDY; PATIENT MONITORING; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PILOT PROJECTS; TUMOR MARKERS, BIOLOGICAL;

EID: 21244483527     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. De Vita VT, Vincent T, Hellman S and Rosenberg A: Cancer of the colon. In: Cancer: Principles and Practise of Oncology. Lippincott - Raven Publishers, s. 1144-1182, 1997.
2. Bast RC, Bates S, Bredt AB et al: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14: 2843-2877, 1996.
3. Patz EF: Principles of imaging. In: Cancer Medicine, 6th ed., Kufe DW (ed.), BC Decker Inc. Hamilton. London, pp. 503-505, 2003.
4. Molina R, Filella X, Zanon G, Pahisa J, Alicarte J, Munoz M, Farrus B and Ballesta AM: Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. Anticancer Res 23(2A): 1043-50, 2003.
5. European Group on Tumor Markers: Consensus Recommendations. Anticancer Res 19: 2785-2820, 1999.
6. Fleisher M et al: Practice guidelines and recomendations for use of tumor markers in the clinic. Lab Med Pract Guidelines 15: 5-56, 2002.
7. Jordan CV: Estrogens and antiestrogens. In: Cancer Medicine, 6th ed., Kufe DW (ed.), BC Decker Inc., Hamilton, London, 939-947, 2003.
8. Penault-Llorca F, Cayre A, Bouchet Mishellany F, Amat S, Feillel V, Le Bouedec G, Ferriere JP, De Latour M and Chollet P: Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 22(6): 1319-25, 2003.
9. Klapdor R, Bahlo M and Babinski A: Atypical courses of serum tumor markers-4 case reports. Anticancer Res 23(2A): 845-50, 2003.
10. Schneider J and Schulze G: Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res 23(6D): 5089-93, 2003.
11. Trape J, Buxo J, Perez de Olaguer J and Vidal C: Tumor markers as prognostic factors in treated non-small cell lung cancer. Anticancer Res 25(5b): 4277-81, 2003.
12. Liu ET: Molecular oncodiagnostics: where we are and where we need to go. J Clin Oncol 21(11): 2052-5, 2003.
13. Miura M, Ichikawa Y, Tanaka K, Kamiyama M, Hamaguchi Y, Ishikawa T, Yamaguchi S, Togo S, Ike H, Ooki S and Shimada H: Real-time PCR (TaqMan PCR) quantification of carcinoembryonic antigen (CEA) mRNA in the peripheral blood of colorectal cancer patients. Anticancer Res 23(2B): 1271-6, 2003.
14. Nakagoe T, Tsuji T, Sawai T, Tanaka K, Hidaka S, Shibasaki S, Nanashima A, Yamaguchi H, Yasutake T, Sugawara K, Inokuchi N and Kamihira S: The relationship between circulating interleukin-6 and carcinoembryonic antigen in patients with colorectal cancer. Anticancer Res 23(4): 3561-4, 2003.
15. Beretta GD and Labianca R: Individual tailored chemotherapy. Suppl Tumori: 1(6): 25-7, 2002.